Bristol Myers Squibb Company
NEWS
It was a busy week for clinical trial announcements. Here’s a look.
After the announcement, Nektar shares dropped 36%, going from $6.47 per share to $4.16.
Bristol Myers Squibb and Nektar Therapeutics said their joint Phase III PIVOT IO-001 study did not meet two endpoints: progression-free survival and objective response rate.
The FDA has a full PDUFA calendar for the second half of March for New Drug Applications and Biologics License Applications. Here’s a look.
Bristol Myers Squibb’s moneymaker cancer drug Revlimid has finally found a competitor in Israel-based Teva Pharmaceuticals’ generic version, lenalidomide.
Sage and Biogen announced positive topline results from the Phase III study of zuranolone that showed a rapid reduction in depressive symptoms after three days.
Bristol Myers Squibb and Exelixis reported two-year follow-up data from the Phase III trial of BMS’s checkpoint inhibitor Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib).
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended 14-1 that the two companies conduct a trial applicable to the U.S. population.
Gilead Sciences revealed in a call with analysts that the hold has now been expanded to additional magrolimab studies.
JOBS
IN THE PRESS